GlassScriptPhysician profile
Neal Dunlap
NPI 1932310422
$97,865.86
in general payments reported to CMS, 2019-2025
40 companies · $16K in 2025
The $16K reported for 2025 was more than what 98% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $18K · 2021: $1,637 · 2022: $15K · 2023: $18K · 2024: $4,414 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Travel and Lodging: $4,996 · Food and Beverage: $2,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,770.00 |
| Travel and Lodging | $4,996.39 |
| Food and Beverage | $2,309.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $89,997.10 | 2019-2025 | Imfinzi, Tagrisso |
| Brainlab, INC. | $3,394.29 | 2025 | Brainlab, INC. |
| Accuray Incorporated | $1,431.34 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $582.32 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Siemens Medical Solutions USA, INC. | $546.97 | 2023 | Truebeam |
| Amgen INC. | $229.83 | 2019-2020 | |
| Gt Medical Technologies, INC | $133.22 | 2022 | |
| Novartis Pharmaceuticals Corporation | $132.38 | 2019-2025 | |
| Monteris Medical Corporation | $129.73 | 2022 | |
| Novocure INC. | $118.55 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.98 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $109.58 | 2019-2025 | Opdivo, Opdualag |
| Foundation Medicine, INC. | $81.32 | 2019-2023 | Foundationone Cdx |
| Incyte Corporation | $75.48 | 2019-2024 | Jakafi |
| Regeneron Healthcare Solutions, INC. | $69.21 | 2020-2025 | Libtayo |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $67.83 | 2024-2025 | Orgovyx |
| Genzyme Corporation | $60.75 | 2019-2021 | |
| Lilly USA, LLC | $57.74 | 2019-2024 | Verzenio, Retevmo, Jaypirca |
| Stemline Therapeutics INC. | $54.10 | 2024-2025 | Elzonris, Orserdu |
| Celgene Corporation | $45.34 | 2019 | |
| Genentech USA, INC. | $44.29 | 2024-2025 | Tecentriq |
| Boston Scientific Corporation | $44.10 | 2022-2025 | Spaceoar Vue System - 10ml |
| Seagen INC. | $35.05 | 2020-2023 | Tukysa |
| Reflexion Medical, INC. | $34.40 | 2023 | Reflexion Medical Radiotherapy System |
| Daiichi Sankyo INC. | $28.67 | 2024 | Enhertu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.59 | 2025 | |
| Ambu INC. | $21.34 | 2021 | |
| Pharmacosmos Therapeutics INC. | $20.34 | 2024 | Cosela |
| Janssen Biotech, INC. | $18.93 | 2023 | Imbruvica, Darzalex |
| Elekta, INC. | $17.64 | 2022 | |
| G1 Therapeutics, INC. | $17.46 | 2023 | Cosela |
| Jazz Pharmaceuticals INC. | $17.14 | 2020 | |
| Genmab U.S., INC. | $16.93 | 2023 | Epkinly |
| Immunocore Limited | $16.50 | 2025 | Kimmtrak |
| Eisai INC. | $15.26 | 2019 | |
| Beigene USA, INC. | $13.75 | 2023 | Brukinsa |
| Karyopharm Therapeutics INC. | $13.05 | 2020 | |
| Aurobindo Pharma USA, INC. | $12.79 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $12.30 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neal Dunlap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.